CALGB-10501 Pre-Registration Worksheet Form Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia Source Form: NCI FormBuilder:

  1. 9/19/12 9/19/12 -
  2. 1/9/15 1/9/15 - Martin Dugas
  3. 1/9/15 1/9/15 - Martin Dugas
  4. 9/17/21 9/17/21 -
Uploaded on:

September 17, 2021

To request one please log in.
License :
Creative Commons BY-NC 3.0 Legacy
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Leukemia NCT00513747 Registration - CALGB-10501 Pre-Registration Worksheet Form - 2660322v1.0

Endocrine Therapy in Combination with Anti-VEGF Therapy: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy plus for Women with Hormone Receptor-Positive Advanced Breast Cancer

Header Module
Protocol Administration
Patient Demographics/pre-treatment Characteristics
Race (Mark all that apply)
Ethnicity (Mark one)
Patient Demographics/pre-treatment Characteristics2
Certification Of Eligibility And Protocol Design
In the opinion of the investigator, is the patient eligible?
Patient has consented to take part in the Quality of Life Study
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for specimen use for research on the patient's cancer?
Patient's Initial Consent given for specimen use for research unrelated to the patient's cancer?
Patient's initial consent given for further contact regarding specimen?
Registration Information

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial